Showing results (2431-2440 of 3,717) with videos related to

Sort By:
Pageof 372
Investigational New Drugs|September 2, 2011
Biological evaluation of MR36, a novel non-polyglutamatable thymidylate synthase inhibitor that blocks cell cycle progression in melanoma cell linesStefania Giudice, Luisa Benassi, Giorgia Bertazzoni, et al.
Investigational New Drugs|September 21, 2011
Phase I combination study of trabectedin and capecitabine in patients with advanced malignanciesLia Gore, E Rivera, M Basche, et al.
Investigational New Drugs|June 3, 2011
Enhanced cell cycle perturbation and apoptosis mediate the synergistic effects of ST1926 and ATRA in neuroblastoma preclinical modelsAngela Maria Di Francesco, Paolo Ubezio, Anna Rita Torella, et al.
Investigational New Drugs|May 1, 1990
Cytotoxicity of diethyldithiocarbamate in human versus rodent cell linesJ D Cohen, H I Robins
Investigational New Drugs|January 5, 2012
Phase I dose-escalating study of ES-285 given as a three-hour intravenous infusion every three weeks in patients with advanced malignant solid tumorsC Massard, R Salazar, J P Armand, et al.
Investigational New Drugs|March 7, 2012
Phase I trial of dasatinib and ixabepilone in patients with solid tumorsP Herbolsheimer, R Kapoor, K L Smith, et al.
Investigational New Drugs|March 10, 2012
Phase II study of bevacizumab and erlotinib in the treatment of advanced hepatocellular carcinoma patients with sorafenib-refractory diseaseThomas Yau, Hilda Wong, Pierre Chan, et al.
Investigational New Drugs|August 25, 2011
A phase I trial of PX-12, a small-molecule inhibitor of thioredoxin-1, administered as a 72-hour infusion every 21 days in patients with advanced cancers refractory to standard therapyRamesh K Ramanathan, Joe J Stephenson, Glen J Weiss, et al.
Investigational New Drugs|July 13, 2011
Topical treatment of cutaneous metastases of malignant melanoma using combined imiquimod and 5-fluorouracilValerie Florin, Eve Desmedt, Sophie Vercambre-Darras, et al.
Investigational New Drugs|July 13, 2011
Figitumumab combined with carboplatin and paclitaxel in treatment-naïve Japanese patients with advanced non-small cell lung cancerYasushi Goto, Ikuo Sekine, Maki Tanioka, et al.
Pageof 372